CAI

NASDAQ Healthcare

Caris Life Sciences, Inc. - Common Stock

Biotechnology

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

๐Ÿ“Š Market Data
Price$21.63
Volume2,756,386
Market Cap6.11B
RSI (14-Day)77.5 Overbought
200-Day MA$21.11
50-Day MA$17.74
52-Week High$42.50
52-Week Low$14.19
P/E Ratio2.26
Forward P/E57.24
Price / Book10.33
๐ŸŽฏ Investment Strategy Scores

CAI scores across each investment strategy. Higher is better for that strategy's goals.

High dividend yield + low volatility
๐Ÿš€ Moon Shot 2/100โ€” 0
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 24/100โ–ฒ +3
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 92/100โ–ผ -1
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐ŸŽˆ Over-Hyped (92/100) โ€” this strategy Overbought stocks (potential short candidates).

Lowest fit among scored strategies: ๐Ÿš€ Moon Shot (2/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find CAI in your text

Paste any article, transcript, or post โ€” the tool will extract CAI and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.